Aileron Therapeutics Inc ALRN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/17/24 EDT
3.77quote price arrow down-0.08 (-2.08%)
Volume
19,489
52 week range
1.01 - 7.42
Loading...
  • Open3.85
  • Day High3.85
  • Day Low3.70
  • Prev Close3.85
  • 52 Week High7.42
  • 52 Week High Date04/18/24
  • 52 Week Low1.01
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap79.705M
  • Shares Out21.14M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta2.12
  • YTD % Change23.66

KEY STATS

  • Open3.85
  • Day High3.85
  • Day Low3.70
  • Prev Close3.85
  • 52 Week High7.42
  • 52 Week High Date04/18/24
  • 52 Week Low1.01
  • 52 Week Low Date10/31/23
  • Market Cap79.705M
  • Shares Out21.14M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta2.12
  • YTD % Change23.66

RATIOS/PROFITABILITY

  • EPS (TTM)-3.39
  • P/E (TTM)-1.11
  • Fwd P/E (NTM)-6.06
  • EBITDA (TTM)-15.229M
  • ROE (TTM)-123.34%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aileron Therapeutics Inc

 

Profile

MORE
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its...
Josef von Rickenbach
Independent Chairman of the Board
Brian Windsor Ph.D.
President, Chief Executive Officer, Director
Address
12407 N. Mopac Expy., Suite 250 #390
Austin, TX
78758
United States